Recurrent Thrombophlebitis
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Recurrent thrombophlebitis is an emerging landscape with 25 programs across 16 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Otsuka, AstraZeneca. 21 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
80%
Small molecule
20 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 25 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)